Quantcast

Gilead Sciences To Buy Cell Design Labs In $567 Mln Deal


Shutterstock photo

(RTTNews.com) - Gilead Sciences Inc. ( GILD ) and its cell therapy subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy.

As per the terms of the agreement, Gilead will acquire all of the outstanding shares of Cell Design Labs, which includes the approximately 12.2 percent of shares of Cell Design Labs that are currently held by Kite, for up to approximately $567 million.

The agreement includes an initial upfront payment of approximately $175 million, subject to certain adjustments, and additional payments of up to $322 million that will be paid to the shareholders of Cell Design Labs other than Kite upon the occurrence of certain events, including the achievement of development and approval milestones.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com




This article appears in: World Markets , Stocks
Referenced Symbols: GILD


More from RTT News

Subscribe






See headlines for GILD









Research Brokers before you trade

Want to trade FX?